X-chromosome biology and immune health in females

XX-Health aims to uncover the role of X-inactivation escape genes in T-cell responses and sex differences in autoimmune disease risk using a novel TriX-Seq methodology in a large female cohort.

Subsidie
€ 1.998.891
2022

Projectdetails

Introduction

Females have a higher risk for autoimmune disease and lower risk of mortality from infectious disease than males, reflecting a more robust immune response in females against both self-antigens (autoimmunity) and non-self-antigens (infections). Genes that escape the process of X-inactivation (XCI) are present in a higher dose in female cells and many play key roles in T-cell biology. XX-Health will reveal the role of escape genes in mediating sex differences in T-cell response.

X-Chromosome Inactivation

Different cells in a tissue can inactivate the maternal (Xm) or paternal X-chromosome (Xp) (mosaicism). In addition, different ratios of Xm and Xp may become silenced in cells of a given tissue, resulting in skewed X-inactivation (sXCI), rendering functional dissection of XCI very challenging.

Rare females (~1:300) inactivate the same parental X-chromosome in all cells (cXCI), removing the confounding effect of mosaicism and offering a powerful genetic system in which to dissect XCI in T-cell biology.

Methodology

We will develop a novel methodology, TriX-Seq, allowing high-resolution screening of sXCI and cXCI in a large (N~8,000) unselected cohort of females. Using T-cells isolated from identified cXCI females, we will:

  1. Generate a unique multi-omic map of XCI during human T-cell differentiation at a resolution well beyond the state-of-the-art.
  2. Directly test the function of alleles specifically expressed from the inactive X-chromosome (Xi) in T-cell biology.

With sXCI data in hand, we will also reveal the associations, if any, of sXCI with disease risk and use the unique availability of parental and grand-parental DNA to assess the genetic origin of cXCI.

Significance

Sex-bias in COVID-19 mortality has highlighted the importance of sex as a contributor to disease risk. The technical and conceptual advances delivered by XX-Health will make a seminal contribution to our understanding of this poorly understood component of human health.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.998.891
Totale projectbegroting€ 1.998.891

Tijdlijn

Startdatum1-11-2022
Einddatum31-10-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • LINKOPINGS UNIVERSITETpenvoerder

Land(en)

Sweden

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Uncovering the missing X factors to understand sex bias in cardiovascular disease

EscapeX aims to uncover sex-specific mechanisms in cardiovascular disease by studying escaper genes and their impact on heart health in a transgenic mouse model, leading to potential new therapies.

€ 1.491.750
ERC Consolid...

Discover the physiological and developmental functions of X chromosome dosage using new genetic and system models

This project aims to uncover the mechanisms of X monosomy lethality and the role of sex chromosome dosage in development using advanced fly genetics and novel insect models.

€ 1.983.769
ERC Starting...

Dissecting the context-specificity of genetic immune regulation in plasmacytoid dendritic cells

The project aims to uncover the genetic regulation and functional diversity of plasmacytoid dendritic cells to explain variability in antiviral responses and autoimmune diseases across diverse populations.

€ 1.499.235
ERC Starting...

Regulation of gene dosage on the mouse X chromosome

REGULADOSIX aims to uncover the evolutionary and functional mechanisms of X-chromosome inactivation in mammals by studying gene dosage compensation during mouse embryogenesis.

€ 1.954.154
ERC Starting...

Deciphering Gene Regulatory Networks governing Mammalian Sex Determination

This project aims to unravel the gene regulatory networks of mammalian sex determination using advanced techniques to enhance understanding of gonad development and related disorders.

€ 1.651.868